CVS Health Co. (NYSE:CVS) Holdings Increased by Larson Financial Group LLC

Larson Financial Group LLC increased its stake in CVS Health Co. (NYSE:CVS) by 874.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,452 shares of the pharmacy operator’s stock after acquiring an additional 5,790 shares during the period. Larson Financial Group LLC’s holdings in CVS Health were worth $509,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. 1900 Wealth Management LLC bought a new position in shares of CVS Health during the 3rd quarter valued at about $219,000. Exchange Traded Concepts LLC boosted its holdings in CVS Health by 22.8% during the third quarter. Exchange Traded Concepts LLC now owns 5,993 shares of the pharmacy operator’s stock worth $418,000 after buying an additional 1,112 shares in the last quarter. Private Trust Co. NA grew its position in CVS Health by 21.9% in the third quarter. Private Trust Co. NA now owns 17,253 shares of the pharmacy operator’s stock worth $1,205,000 after buying an additional 3,103 shares during the last quarter. Riverwater Partners LLC increased its holdings in shares of CVS Health by 24.3% in the third quarter. Riverwater Partners LLC now owns 4,205 shares of the pharmacy operator’s stock valued at $294,000 after buying an additional 821 shares in the last quarter. Finally, LaFleur & Godfrey LLC lifted its position in shares of CVS Health by 1.2% during the 3rd quarter. LaFleur & Godfrey LLC now owns 29,806 shares of the pharmacy operator’s stock valued at $2,081,000 after acquiring an additional 345 shares during the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Prem S. Shah sold 29,473 shares of CVS Health stock in a transaction on Friday, February 16th. The shares were sold at an average price of $76.95, for a total value of $2,267,947.35. Following the completion of the sale, the executive vice president now owns 39,765 shares of the company’s stock, valued at approximately $3,059,916.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 0.24% of the company’s stock.

CVS Health Trading Down 1.6 %

NYSE CVS opened at $68.50 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.63 and a debt-to-equity ratio of 0.77. CVS Health Co. has a 1-year low of $64.41 and a 1-year high of $83.25. The firm’s fifty day simple moving average is $74.97 and its 200-day simple moving average is $73.76. The company has a market capitalization of $86.34 billion, a PE ratio of 10.60, a price-to-earnings-growth ratio of 0.92 and a beta of 0.52.

CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, February 7th. The pharmacy operator reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.11. The company had revenue of $93.81 billion for the quarter, compared to analyst estimates of $90.58 billion. CVS Health had a return on equity of 15.25% and a net margin of 2.33%. The business’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.99 EPS. As a group, sell-side analysts anticipate that CVS Health Co. will post 8.31 earnings per share for the current fiscal year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Monday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.88%. The ex-dividend date is Friday, April 19th. CVS Health’s dividend payout ratio (DPR) is presently 41.18%.

Analysts Set New Price Targets

CVS has been the topic of a number of recent research reports. Leerink Partnrs restated an “outperform” rating on shares of CVS Health in a report on Monday, February 26th. SVB Leerink began coverage on CVS Health in a report on Monday, February 26th. They set an “outperform” rating and a $88.00 price objective on the stock. Barclays initiated coverage on shares of CVS Health in a report on Wednesday, March 6th. They issued an “equal weight” rating and a $78.00 target price for the company. StockNews.com lowered shares of CVS Health from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $87.00 price objective on shares of CVS Health in a research note on Wednesday, April 10th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $89.44.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.